Drug
Gallium 68 PSMA-11 clinical trials
Also written 68Ga-PSMA-11, AAA 517 and DFKZ 11.
Keep track of what changes. Save the gallium 68 PSMA-11 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Other names
Combined with it in one product
Studies by the year they started
63 studies that test it; most in 2020 (11)
| Year | Studies |
|---|---|
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 6 |
| 2018 | 5 |
| 2019 | 6 |
| 2020 | 11 |
| 2021 | 9 |
| 2022 | 6 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 59
Mayo Clinic (7) · Andrei Iagaru (5) · Thomas Hope (4) · Jonsson Comprehensive Cancer Center (4) · Peking Union Medical College Hospital (4) · University of California, San Francisco (3) · First Affiliated Hospital of Fujian Medical University (3) · Telix Pharmaceuticals (Innovations) Pty Limited (2)
Often tested with
Tested in the same studies.
Rm-2 ga-68 (5) · Lutetium (¹⁷⁷Lu) vipivotide tetraxetan (1) · PSMA-1007 F-18 (1) · Sodium Glutamate (1) · Fluciclovine F-18 (1) · 89Zr-Df-IAB2M (1) · 68 Ga-P16-093 (1) · Vipivotide tetraxetan gallium GA-68 (1)
Studies
Open first, then newest update. How each study uses gallium 68 PSMA-11 is read from its arms, and is right about nine times in ten.
Testing it · 63
- Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy DeliveryNot yet recruitingEarly Phase 1University of Texas Southwestern Medical CenterNCT07674771Written as Drug: 68-Ga PSMA11
- 68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal TherapyNot yet recruitingNot applicableUniversity Health Network, TorontoNCT07747493Written as Gallium Ga 68 Gozetotide (68Ga-PSMA-11)
- An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With GliomaRecruitingPhase 2Mayo ClinicNCT06444412Written as Ga 68 PSMA-11
- PSMA PET Response Guided SabR in High Risk PcaRecruitingPhase 1University of Texas Southwestern Medical CenterNCT06044857Written as 68-Ga PSMA11
- 68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRIRecruitingPhase 2/3First Affiliated Hospital of Fujian Medical UniversityNCT07209878Written as 68Ga-PSMA-11
- 68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer PatientsRecruitingNot applicablePeking Union Medical College HospitalNCT05324332Written as 68Ga-PSMA-11
- Preoperative Planning With PSMA-PET in Melanoma Surgery TrialRecruitingPhase 2Royal Marsden NHS Foundation TrustNCT06560905Written as 68Ga-PSMA
- 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese PatientsRecruitingPhase 3Telix Pharmaceuticals (Innovations) Pty LimitedNCT05847348Written as 68Ga-PSMA-11
- PET/MRI to Stage Prostate Cancer PatientsRecruitingPhase 2IRCCS San RaffaeleNCT06484361Written as 68Ga-PSMA
- 68Ga-AAZTA-093 PET/CT: First-in-human StudyRecruitingEarly Phase 1First Affiliated Hospital of Fujian Medical UniversityNCT06437496Written as 68Ga-PSMA-11//68Ga-PSMA-617
- 68Ga-PSMA-11 PET/CT in Patients With Various Types of CancerRecruitingEarly Phase 1First Affiliated Hospital of Fujian Medical UniversityNCT04831541Written as 68Ga-PSMA-11
- 68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate CancerCompletedPhase 1City of Hope Medical CenterNCT04216134Written as Gallium Ga 68-labeled PSMA-11
- PSMA PET Combined With MRI for the Detection of PCaActive, not recruitingPhase 3Telix Pharmaceuticals (Innovations) Pty LimitedNCT07052214Written as 68Ga-PSMA-11
- 68Ga PSMA PET Imaging for the Treatment of Advanced Liver CancerCompletedPhase 2Mayo ClinicNCT05176223Written as Gallium Ga 68 Gozetotide
- 68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver CancerCompletedPhase 2Mayo ClinicNCT04762888Written as Gallium Ga 68 Gozetotide
- Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal FunctionActive, not recruitingPhase 2Novartis PharmaceuticalsNCT06004661Written as 68Ga-PSMA-11
- 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate CancerTerminatedPhase 2Thomas HopeNCT04716725Written as 68Ga-PSMA-11
- An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate CancerActive, not recruitingPhase 2University of WashingtonNCT04777071Written as Gallium Ga 68 Gozetotide
- Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPCWithdrawnPhase 1/2Novartis PharmaceuticalsNCT06881823Written as Gallium (68Ga) gozetotide
- PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot StudyTerminatedPhase 2UNC Lineberger Comprehensive Cancer CenterNCT04176497Written as 68Ga-HBED-CC-PSMA
See all 63 studies that test gallium 68 PSMA-11 →
Given in every arm · 10 — gallium 68 PSMA-11 is usual care beside what is tested
- Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate CancerRecruitingPhase 1Weill Medical College of Cornell UniversityNCT04886986Written as 68Ga-PSMA-11
- Phase 2 Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruitingPhase 2First Affiliated Hospital of Fujian Medical UniversityNCT07117760Written as 68Ga-PSMA-11
- A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCActive, not recruitingPhase 2Novartis PharmaceuticalsNCT05849298Written as AAA517
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPCCompletedPhase 2Novartis PharmaceuticalsNCT05670106Written as 68Ga-PSMA-11
- Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPCCompletedPhase 1/2Weill Medical College of Cornell UniversityNCT03042468Written as 68Ga-PSMA-HBED-CC
- 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate CancerActive, not recruitingPhase 3Novartis PharmaceuticalsNCT04689828Written as 68Ga-PSMA-11
- An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT04720157Written as 68Ga-PSMA-11
- Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast CancerCompletedPhase 1Emory UniversityNCT04750473Written as Gallium Ga 68 Gozetotide
- A Trial of CTT1403 for Metastatic Castration Resistant Prostate CancerCompletedPhase 1Cancer Targeted TechnologyNCT03822871Written as 68Ga-PSMA-11
- 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPCTerminatedPhase 1/2Weill Medical College of Cornell UniversityNCT03545165Written as 68Ga-PSMA-HBED-CC
Codes
What other systems call gallium 68 PSMA-11 · ClinicalTrials.gg INT001668
- MeSH (NLM) C000718244gallium 68 PSMA-11One source ClinicalTrials.gov
- UNII (FDA) ZJ0EKR6M10GALLIUM GA-68 GOZETOTIDEConfirmed FDA, Wikidata
- RxNorm 2586016One source FDA
- Wikidata Q27295602gallium 68 PSMA-11Confirmed FDA, Wikidata
- DrugBank DB16019One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718244 | gallium 68 PSMA-11 | One source ClinicalTrials.gov |
| UNII (FDA) | ZJ0EKR6M10 | GALLIUM GA-68 GOZETOTIDE | Confirmed FDA, Wikidata |
| RxNorm | 2586016 | — | One source FDA |
| Wikidata | Q27295602 | gallium 68 PSMA-11 | Confirmed FDA, Wikidata |
| DrugBank | DB16019 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.